OICR supports approximately 1,800 researchers at institutions across the province of Ontario. This page lists the recipients of OICR Investigator Awards, Associates, research fellows and the leaders of OICR’s research programs and initiatives. Find out more about OICR’s Investigator Awards Program.
Dr. Ailles and her team are focusing on two major research areas, intra-tumoural heterogeneity and epigenetics in clear cell renal cell carcinoma (ccRCC).
Dr. Al-awar leads OICR's Drug Discovery group.
Dr. Aldape is an OICR associate.
Dr. Awadalla and his team focuses on next-generation genomics approaches, model-based tools and population-based approaches to study cancer.
Dr. Bartlett is developing new diagnostic approaches to improve patient diagnosis and treatment.
Dr. Bedard is Co-Principal Investigator of the Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study.
Dr. Bell’s lab has shown that a variety of viruses selectively replicate in and kill cancer cell lines while leaving healthy parts of the body intact.
Dr. Boutros' team uses biological big data to create new biomarkers that personalize therapy for individual patients.
Dr. Butler is a co-leader of OICR's Immuno-oncology Translational Research Initiative (ACTION).
Dr. Janet Dancey is the leader of the Canadian Cancer Clinical Trials Network (3CTN) and the Canadian Cancer Trials Group (CCTG).
Dr. Dick’s world-renowned research program centers on the theme that genetic and non-genetic determinants of tumour heterogeneity are linked through stemness.
Dr. Dirks is a co-leader of OICR's Brain Cancer Translational Research Initiative.
Dr. Feilotter focuses on the development of biomarkers to be used in the screening, diagnosis or treatment of human diseases, including cancer.
Dr. Fenster is driven by the opportunity to use technological innovations to meet the challenges of cancer diagnosis and therapy needs.
Dr. Fiume is an OICR associate.
Dr. Ferretti’s is a bioinformatics leader with experience in both large-scale software development and computational genomics.
Geoffrey T. Fong
Dr. Fong is the founder of the International Tobacco Control Policy Evaluation Project. This project's objective is to evaluate the impact of policies designed to control tobacco use.
Dr. Gallinger is the leader of OICR's Pancreatic Cancer Translational Research Initiative (PanCuRx).
The focus of Dr. Grunfeld’s research is the evaluation of access to and quality of cancer care across the cancer control continuum – from screening to end-of-life care.
Dr. Haibe-Kains is an OICR associate.
Dr. Haider’s research focus is abdominal and pelvic MRI with an interest in therapeutic response assessment and quantitative imaging of cancer.
Dr. Hanna’s research focuses on three translational streams of health services research: quality of care, value of care and access to care.
The overarching goal of Dr. Hirano’s research is to devise novel anti-tumour immunotherapeutic modalities that can cure cancer.
Dr. Hope aims to identify the underlying processes that lead to the transformation of healthy cells into leukemic cells and contribute to the progression of the disease.
Dr. Jamaspishvili is working to identify and validate promising diagnostic and prognostic biomarkers for early prostate cancer.
Dr. Kornaga is an OICR associate.
Dr. LeBrun’s research group studies perturbations in the regulation of gene transcription that underlie acute lymphoblastic leukemia.
Dr. Lupien’s research highlights the need to characterize and understand the role of noncoding regulatory elements as targets of genetic and epigenetic changes in oncogenesis.
Dr. McPherson is an OICR associate specializing in genome technologies.
Dr. Morris is a Senior Investigator and OICR associate.
Dr. Nieman is studying the developmental impact of chemotherapy agents with a goal of improved brain development and quality of life in childhood cancer patients.
Dr. Notta is an OICR associate.
Dr. Oza co-leads OICR's Ovarian Cancer Translational Research Initiative.
Dr. Palma's research focuses on new imaging technologies used with radiotherapy to improve tumour targeting and to deliver higher doses of radiotherapy than previously possible.
Dr. Pearson’s lab is working to understand the connection between adult stem cells and cancer by using the freshwater planarian as an in vivo model system.
Dr. Pond’s research interest is in statistical methodologies and analysis of cancer clinical trials, with an aim to facilitate the translation of scientific discoveries into the clinic.
Dr. Pugh is leader of the Princess Margaret-OICR Translational Genomics Laboratory and an OICR associate.
The Reimand Lab develops and applies methods to interpret cancer data using pathway and network information.
The Rottapel Lab uses functional genetic screens (both shRNA and CRISPR/Cas9) to identify novel vulnerabilities in ovarian cancer as a strategy to develop new therapeutic targets.
Dr. Schimmer is the co-leader of OICR's Acute Leukemia Translational Research Initiative.
Dr. Scholl is focusing on developing an emergent technique for molecular imaging with magnetic resonance.
The Simpson Lab develops algorithms and software for the analysis of high-throughput sequencing data.
Dr. Siu is Co-Principal Investigator of the Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study.
Dr. Soave is an OICR associate specialized in biostatistics and longitudinal data analysis.
Dr. Stein is the leader of Adaptive Oncology at OICR.
Dr. Taylor is the co-leader of OICR's Brain Cancer Translational Research Initiative.
Dr. Wouters’ lab has identified new signaling pathways that influence how tumours respond to environments with reduced oxygenation.
Dr. Yaffe’s research is directed toward development and improvement of imaging techniques for the earlier detection, diagnosis and treatment of cancer.
Dr. Yung is the Director of Genome Informatics at OICR.